First-in-Class CAR-T for Solid Tumors – The Global First That Changes Everything

I. Introduction: A Historic Milestone in Cancer Immunotherapy

On June 22, 2026, China's National Medical Products Administration (NMPA) approved a therapy that will be remembered as a turning point in the history of cancer treatment. Shurui Jiao'ao CAR-T (Shurui®) – developed by Shanghai-based CARsgen Therapeutics – became the world's first approved CAR-T cell therapy for solid tumors.

For over a decade, chimeric antigen receptor T-cell (CAR-T) therapy had been one of the most exciting frontiers in oncology. But it carried a significant limitation: it worked remarkably well for blood cancers — leukemias, lymphomas, and multiple myeloma — but consistently failed against solid tumors, which account for over 90% of all cancers.

The approval of Shurui Jiao'ao CAR-T changes that paradigm. For the first time, a CAR-T therapy has demonstrated clinically meaningful efficacy in a solid tumor indication — advanced gastric cancer and gastroesophageal junction adenocarcinoma. This is not just a breakthrough for China — it is a breakthrough for the entire field of cancer immunotherapy.

II. The Challenge: Why Solid Tumors Are Different

To understand why this approval is so significant, it is essential to understand why CAR-T has historically struggled against solid tumors.

Solid tumors present unique challenges:

• Tumor microenvironment (TME): Solid tumors create a hostile microenvironment that suppresses T-cell activity. Tumors secrete immunosuppressive molecules — TGF-β, IL-10, and other cytokines — that effectively "turn off" infiltrating T-cells.
• Physical barriers: Dense stromal tissue and abnormal vasculature make it difficult for CAR-T cells to penetrate solid tumor masses.
• Antigen heterogeneity: Unlike many blood cancers where tumor cells uniformly express a single target antigen (e.g., CD19), solid tumors are highly heterogeneous — different cells within the same tumor may express different antigens, making it easier for tumors to escape immune attack.
• On-target, off-tumor toxicity: Many tumor-associated antigens are also expressed on healthy tissues, raising the risk of severe side effects.

These challenges led many experts to conclude that CAR-T might never work for solid tumors. CARsgen's success changes that narrative.

III. The Breakthrough: Shurui Jiao'ao CAR-T (Shurui®)

Drug Overview

Aspect	Details
Product Name	Shurui Jiao'ao CAR-T (Shurui®)
Developer	CARsgen Therapeutics (Shanghai)
Target Antigen	Claudin 18.2 (CLDN18.2)
Indication	Previously treated CLDN18.2-positive advanced gastric cancer and gastroesophageal junction adenocarcinoma
Approval Date	June 22, 2026
Global Significance	World's first approved CAR-T therapy for solid tumors
Regulatory Pathway	Priority review and conditional approval

Why Claudin 18.2?

Claudin 18.2 (CLDN18.2) is a tight junction protein that is normally expressed only in gastric mucosal cells. However, in gastric cancer, it becomes aberrantly overexpressed and exposed on the cell surface — making it an ideal tumor-specific target. Importantly, CLDN18.2 expression is preserved in 60%–80% of gastric cancer patients, making it one of the most promising targets for this indication.

Because CLDN18.2 expression is restricted to gastric tissue, the risk of "on-target, off-tumor" toxicity is more manageable than with many other solid tumor targets — a critical factor that contributed to the therapy's favorable safety profile.

Clinical Data

The approval was based on data from the pivotal Phase II clinical trial (CT041-ST-01), which demonstrated:

• Objective response rate (ORR): Clinically meaningful responses in heavily pretreated patients who had exhausted standard treatment options
• Durable responses: Responses lasting for several months, with some patients achieving prolonged disease control
• Manageable safety profile: The most common adverse events were cytokine release syndrome (CRS) of Grade 1–2, consistent with CAR-T therapy, with no unexpected toxicities

The therapy demonstrated that CAR-T can work in solid tumors — not just in theory, but in practice.

IV. The Science Behind the Success

CARsgen's achievement was not a stroke of luck. It reflects years of careful scientific and clinical development.

Key innovations included:

1. Optimal target selection: CLDN18.2 is a validated, tumor-specific antigen with high and homogeneous expression in gastric cancer.
2. Optimized CAR design: CARsgen developed a proprietary CAR construct with optimized signaling domains to enhance T-cell persistence and function in the solid tumor microenvironment.
3. Manufacturing excellence: CARsgen established robust manufacturing processes capable of consistently producing high-quality CAR-T products for clinical use.
4. Strategic clinical development: The company carefully designed clinical trials with appropriate patient selection, using validated CLDN18.2 diagnostic assays to identify eligible patients.

V. The Global Context: A Milestone for Cancer Immunotherapy

The approval of Shurui Jiao'ao CAR-T places China at the forefront of CAR-T innovation.

The CAR-T Landscape Before This Approval

Prior to June 2026, all approved CAR-T therapies targeted hematological malignancies — cancers of the blood and bone marrow:

• Kymriah (tisagenlecleucel, Novartis) — B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma
• Yescarta (axicabtagene ciloleucel, Gilead/Kite) — Diffuse large B-cell lymphoma
• Breyanzi (lisocabtagene maraleucel, BMS/Juno) — Diffuse large B-cell lymphoma
• Tecartus (brexucabtagene autoleucel, Gilead/Kite) — Mantle cell lymphoma, B-cell ALL
• Abecma (idecabtagene vicleucel, BMS/Bluebird) — Multiple myeloma
• Carvykti (ciltacabtagene autoleucel, J&J/Legend Biotech) — Multiple myeloma

None had succeeded in solid tumors — until now.

Why This Matters for Patients

For patients with advanced gastric cancer — one of the most difficult cancers to treat — the approval of Shurui Jiao'ao CAR-T offers:

• A new treatment option for patients who have progressed on standard chemotherapy and immunotherapy
• Durable responses that may extend survival
• The possibility of long-term disease control, unlike conventional chemotherapy which often provides only transient benefit

Why This Matters for the Field

The approval is a proof-of-concept that:

• CAR-T can work in solid tumors with the right target and design
• The challenges of the tumor microenvironment are surmountable
• China's biopharmaceutical sector can develop truly first-in-class therapies

VI. China's CAR-T Regulatory Environment

China has developed a sophisticated regulatory framework for CAR-T therapies, which has contributed to the rapid advancement of the field.

Key Regulatory Features:

1. Priority Review Pathway: CAR-T therapies for serious diseases with no satisfactory treatment options are eligible for priority review.
2. Conditional Approval Pathway: Therapies demonstrating significant clinical benefit based on Phase II data can receive conditional approval, with post-marketing confirmatory studies required.
3. Specific Guidelines for Cellular Therapies: NMPA has issued dedicated guidelines for CAR-T and other cell-based therapies, providing clear development and regulatory pathways.
4. Fast-Track Clinical Trial Approval: The IND 30-day silent approval pathway enables rapid initiation of clinical trials.

This regulatory environment has made China a global leader in CAR-T development, with more than 400 active CAR-T clinical trials as of 2025 — more than any other country.

VII. What This Means for International Patients

For international patients considering treatment in China, the approval of Shurui Jiao'ao CAR-T represents:

• Access to a world-first therapy not available anywhere else
• Expertise from one of the world's leading CAR-T research and clinical centers
• Quality manufacturing meeting international standards
• Competitive pricing compared to CAR-T therapies in the U.S. and Europe, which typically cost $400,000–$500,000 per treatment

Important considerations for patients:

• The therapy is approved for CLDN18.2-positive gastric cancer and gastroesophageal junction adenocarcinoma
• Eligible patients must undergo testing to confirm CLDN18.2 expression
• Patients should discuss the treatment with their oncologist to determine if they are suitable candidates

VIII. Future Directions

The approval of Shurui Jiao'ao CAR-T is just the beginning. CARsgen and other Chinese companies are working to expand CAR-T to additional solid tumor indications.

Other CAR-T Candidates in China's Pipeline:

Target	Company	Indication	Status
GPC3	CARsgen	Hepatocellular carcinoma	Phase II
B7-H3	Multiple companies	Multiple solid tumors	Phase I/II
MSLN	Various	Mesothelioma, ovarian cancer	Phase I/II
EGFR	Various	NSCLC, glioblastoma	Phase I
HER2	Various	Breast cancer, gastric cancer	Phase I/II
Claudin 18.2	Multiple companies	Gastric cancer	Various phases

IX. Conclusion: A New Era Begins

The approval of the world's first CAR-T for solid tumors is a milestone that will be remembered in the history of oncology. For decades, immunotherapy researchers dreamed of harnessing the power of the immune system to fight all cancers — not just blood cancers. With the approval of Shurui Jiao'ao CAR-T, that dream is now a reality for gastric cancer patients.

For China, this approval cements its position as a global leader in cell and gene therapy. For the field, it proves that CAR-T can work in solid tumors — opening the door to countless new applications. And for patients, it offers hope where there was previously none.

The era of CAR-T for solid tumors has begun — and China is leading the way.